Novartis has a sound strategy to navigate a world with a growing, aging population and continuously evolving healthcare needs. Our mission and vision complement our strategy, and together they support the creation of value over the long term for our company, our shareholders and society.
Our mission is to discover new ways to improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to provide a shareholder return that rewards those who invest their money, time and ideas in our company.
Our vision is to be a trusted leader in changing the practice of medicine.
Our strategy is to use science-based innovation to deliver better patient outcomes. We aim to lead in growing areas of healthcare. We maintain substantial investment in research and development aimed at areas of unmet medical need. We seek to develop medicines and products that can produce positive real-world outcomes for patients. We are expanding our presence in the emerging markets of Asia, Africa and Latin America, where there is fast-growing demand for access to high-quality medicines and healthcare.
We focus our corporate responsibility work in two key areas: expanding access to healthcare and doing business responsibly. This combination of responsible business and making our medicines accessible is directly linked to our company mission, vision and strategy.
To help us achieve our goal of finding new ways to deliver breakthrough treatments to as many people as possible, our access efforts include an array of social business, zero-profit, philanthropic and patient assistance programs. To help us become a trusted leader in changing the practice of medicine, we are taking steps to ensure our standards align with society’s increasingly high expectations for ethical behavior.
Corporate responsibility (CR) is embedded throughout our company. The commitment and involvement from senior management and the Governance, Nomination and Corporate Responsibilities Committee of the Novartis Board of Directors helps us make the strategic decisions necessary to drive our corporate responsibility programs. The engagement and dedication of our associates help bring all of these initiatives to life.
We are committed to transparent reporting – a central part of our UN Global Compact obligations. Our Annual Report serves as our primary reporting mechanism for corporate responsibility, and we have published a combined financial and CR report since 2000.
The CR Performance Report is based on the Global Reporting Initiative G4 guidelines, with disclosure at “comprehensive” level, making it the first comprehensive level-report in the healthcare industry.